News Acadia, Harmony record late-stage rare disease failures Biotechs Acadia Pharma and Harmony Biosciences both suffered setbacks in phase 3 trials of drugs for rare diseases, in one case ending the programme.
News Joy as uniQure Huntington's therapy clears pivotal trial uniQure's gene therapy AMT-130 has cleared a trial in Huntington's, setting up filings and raising the prospect of a first treatment for the disease.
News BMS eyes filings for myeloma 'celmod' iberdomide Bristol Myers Squibb has said it hopes to be ready soon to file for approval of its multiple myeloma drug iberdomide after a positive phase 3 trial.
News Roche's oral SERD comes good in 2nd-line breast cancer trial Roche has staked a claim to use its oral SERD giredestrant as a second-line therapy for breast cancer, regardless of a patient's ESR1 mutation status.
News Bayer starts pivotal Parkinson's cell therapy trial Bayer's much-anticipated stem cell therapy for Parkinson's disease is gathering momentum, with dosing in phase 3 trials now underway.
News UK specialists call for more testing on psychedelics UK psychiatrists have called for a relaxation of restrictive rules on testing psychedelics, which are holding back research and clinical use.
News Praxis soars on rare childhood epilepsy trial data Praxis looks like it could be filing for approval of two products next year, after its childhood epilepsy drug delivered a win in a pivotal trial.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.